HIV/AIDS

Japan's DNAVEC and IAVI partner on novel AIDS vaccine strategy

Published in Vaccine Weekly, July 25th, 2007

The New York-based International AIDS Vaccine Initiative (IAVI) and DNAVEC Corporation today announced a collaboration to jointly develop an AIDS vaccine using DNAVEC's Sendai virus (SeV) vector technology. The candidate will be designed to be administered intra-nasally to stimulate immune responses in both the blood and mucosal tissues, the initial point of entry for HIV.

This direction in AIDS vaccine development is crucial: Today, most candidates in clinical trials—numbering close to 30—are based on a cell-mediated approach, targeting only one arm of the human immune system. Promising vectors that trigger mucosal immunity at the primary site of infection and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2007-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry